Inhibition of STAT-3 results in radiosensitization of human squamous cell carcinoma

Radiotherapy and Oncology

Volumn 92, Issue 3, 2009, Pages 339-344

  Bonner, James A ^a   Trummell, Hoa Q ^a   Willey, Christopher D ^a   Plants, Brian A ^a   Raisch, Kevin P ^a  

^a The University of Alabama at Birmingham   (United States)

Author keywords

Radiosensitization; STAT 3

Indexed keywords

SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; RADIOSENSITIVITY; RADIOSENSITIZATION; SQUAMOUS CELL CARCINOMA;

APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; HUMANS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR; REFERENCE VALUES; RNA, SMALL INTERFERING; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION;

EID: 69949140389     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2009.06.022     Document Type: Article

References (26)

1. Heimberger A.B., and Priebe W. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Patients CNS Drug Discov 3 (2008) 179-188
2. Yue P., and Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opin Invest Drugs 18 (2009) 45-56
3. Willey C.D., Palanisamy A.P., Johnston R.K., et al. STAT3 activation in pressure-overloaded feline myocardium: role for integrins and the tyrosine kinase BMX. Int J Biol Sci 4 (2008) 184-199
4. Haura E.B., Zheng Z., Song L., et al. Activated epidermal growth factor receptor - STAT-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 11 (2005) 8288-8294
5. Grandis J.R., Drenning S.D., Zeng Q., et al. Constitutive activation of STAT-3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci (PNAS) 97 (2000) 4227-4232
6. Catlett-Falcone R., Landowski T.H., Oshiro M.M., et al. Constitutive activation of STAT-3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10 (1999) 105-115
7. L enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol Pharmacol 73 (2008) 1632-1642
8. Scaltriti M., and Baselga J. The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12 (2006) 5268-5272
9. Aoki Y., Feldman G.M., and Tosato G. Inhibition of STAT-3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. Blood 101 (2003) 1535-1542
10. Bonner J.A., Raisch K.P., Trummell H.Q., et al. Enhanced apoptosis with combination C225/radiation treatment serves as the impetus for clinical investigation in head and neck cancers. J Clin Oncol 18 (2000) 47s-53s
11. Summy J.M., and Gallick G.E. Treatment for advanced tumors: SRC reclaims center stage. Clin Cancer Res 12 (2006) 1398-1401
12. Bonner J.A., Maihle N.J., Folven B.R., et al. The interaction of epidermal growth factor and radiation in human head and neck squamous cell carcinoma cell lines with vastly different radiosensitivities. Int J Radiation Oncology Biol Phys 29 (1994) 243-247
13. Huang S.M., Bock J.M., and Harari P.M. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res 59 (1999) 1935-1940
14. Saleh M.N., Raisch K.P., Stackhouse M.A., et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 14 (1999) 451-463
15. Dobelbower M.C., Russo S.M., Raisch K.P., et al. Epidermal growth factor receptor tyrosine kinase inhibitor, erlotnib, and concurrent 5-fluorouracil, cisplatin and radiotherapy for patients with esophageal cancer: a phase I study. Anti-Cancer Drugs 17 (2006) 95-102
16. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354 (2006) 567-578
17. Fertil B., Dertinger H., Courdi A., et al. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 99 (1984) 73-84
18. Colton T. Statistics in medicine (1974), Little, Brown, Boston, MA 131-136
19. Bonner J.A., Buchsbaum D.J., Russo S.M., et al. Anti-EGFR-mediated radiosensitization as a result of augmented EGFR expression. Int J Radiat Oncol Biol Phys 59 (2004) 2-10
20. Zhang Z., Wang H., Li M., et al. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 279 (2004) 16000-16006
21. Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res 7 (2009) 592-600
22. Onishi A., Chen Q., Humtsoe J.O., et al. STAT3 signaling is induced by intercellular adhesion in squamous cell carcinoma cells. Exp Cell Res 314 (2008) 377-386
23. Turkson J., Ryan D., Kim J.S., et al. Phosphotyrosyl peptides block STAT3-mediated DNA binding activity, gene regulation, and cell transformation. J Biol Chem 276 (2001) 45443-45455
24. Turkson J., Kim J.S., Zhang S., et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther 3 (2004) 261-269
25. Turkson J., Zhang S., Mora L.B., et al. A novel platinum compound inhibits constitutive STAT3 signaling and induces cell cycle arrest and apoptosis of malignant cells. J Biol Chem 280 (2005) 32979-32988
26. Timofeeva O.A., Gaponenko V., Lockett S.J., et al. Rationally designed inhibitors identify STAT3 N-domain as a promising anticancer drug target. ACS Chem Biol 2 (2007) 799-809